Navigation Links
Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
Date:3/8/2010

REDWOOD CITY, Calif., March 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either anastrozole or tamoxifen. The study, originally presented at the San Antonio Breast Cancer Symposium in 2008, was published online today in the Journal of Clinical Oncology.  

The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an RS result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.  As of December 2009, more than 8,000 physicians had used more than 135,000 Oncotype DX breast cancer tests for treatment planning.

"We believe the results of this study reinforce the important role of Oncotype DX in making individualized treatment decisions for early stage breast cancer patients with node-negative and node-positive disease," said Steven Shak, M.D., chief medical officer of Genomic Health.  "Oncotype DX testing allows physicians and patients to make a more informed decision on whether to add chemotherapy, yielding a potential savings to the U.S. healthcare system of approximately $2,000 in direct costs per patient."

The study used Oncotype DX to analyze tumor samples from 1,231 patients involved in the landmark ATAC (Arimidex®, Tamoxifen, Alone or in Combination) trial, which established the extensive use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. Nine-year distant recurrence was assessed for women in the anastrozole and tamoxifen monotherapy arms of the ATAC trial, including patients with disease that had spread to the lymph nodes (0 nodes, 1-3 nodes and 4 or more nodes).

Researchers collected tumor blocks primarily from patients in the United Kingdom and tested the significance of adding the RS result to a clinical model consisting of age, tumor size, grade and treatment, as well Adjuvant! Online, a valid risk assessment tool that evaluates clinical variables to help physicians and patients assess the risks and benefits of getting additional therapy after surgery.

Results indicated that the RS result provided statistically significant prognostic value beyond that provided by Adjuvant! Online in node-negative (p<0.001) patients. While the study confirmed the performance of the RS result in a large contemporary patient population of postmenopausal hormone receptor-positive women treated with tamoxifen, it also demonstrated that the established relationship between the RS and risk of distant recurrence for tamoxifen may now be applied to anastrozole. The greater efficacy of anastrozole observed in the parent ATAC trial and the analysis of the RS results in both treatment arms from this study suggests a lower risk of recurrence in patients treated with aromatase inhibitors. Additionally, as consistent with prior OncotypeDX results in node-positive breast cancer, for any RS result, the likelihood of distant recurrence increases with the number of positive nodes.

About Oncotype DX®

The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer test has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of December 2009, more than 8,000 physicians in over 50 countries had ordered more than 135,000 tests, and both Medicare and private health plans covering over 90 percent of U.S. insured lives provide reimbursement for Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit www.oncotypedx.com.  

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the study data support the clinical utility of our test in postmenopausal breast cancer patients with node-negative or node-positive, hormone receptor-positive disease who are treated with either anastrozole or tamoxifen, the belief that using Oncotype DX for breast cancer can allow better-informed decisions to avoid the toxicity and medical costs of chemotherapy, and the amount of the potential cost savings, the belief that the RS result provided statistically significant prognostic value beyond that provided by Adjuvant! Online, and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to:  the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health

Back to top

RELATED LINKS
http://www.genomichealth.com

'/>"/>

SOURCE Genomic Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... updated financial guidance for 2016 on Thursday, December 15, ... that day with the investment community and media to ... conference call will begin at 10 a.m. ET. Investors, ... webcast of the conference call through a link that ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic ... & Support) is Expected to Gain a Significant Market Share ... Orthopedic Ailments  ... , According to a ... on Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected ...
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
Breaking Medicine Technology:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with ... that works for them. When an inventor from Suisun City, Calif., was unsuccessful in ... share it with others. , He developed a prototype for PRO GO MASSAGE to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi ... be included in the 2016 “Guide to America’s Top Plastic Surgeons” for seven ... amalgamation of their education, experience, and professional associations. , One the most ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to announce ... covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients ... life 6 years in the last 3 decades,” says Dr. Valentine Fuster, a ...
(Date:12/2/2016)... Honolulu, Hawaii (PRWEB) , ... December 02, 2016 ... ... 3, 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, ... (CME) in the field of pain management. , The demand for supplemental ...
Breaking Medicine News(10 mins):